Cohort – Maintaining function and well-being in later life

Title of the cohort
Cohort – Maintaining function and well-being in later life
Acronym for cohort
CFAS Wales
Name of Principal Investigator

Title Professor
First name  Bob
Last name Woods

Address of institution where award is held

Institution Bangor University
Street Address 45, College Road
City Bangor
Postcode LL57 2DG

Country
United Kingdom
Website
http://cfaswales.bangor.ac.uk/
Contact email
[email protected]
Funding source
ESRC
HEFCW
1. The cohort includes, or expects to include, incidence of the following conditions

  • Alzheimer’s disease and other dementias

When studies on the above condition(s) are expected to become possible
2016 – 2025
2a. Stated aim of the cohort
To identify biopsychosocial influences on the development of cognitive impairment and the maintenance of well-being in later life.
2b. Features distinguishing this cohort from other population cohorts
This cohort links in with the CFAS-II study, but includes additional measures relating to social support, bilingualism and resilience.
3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort
Will augment the CFAS-II study, in comparing prevalence and incidence of cognitive impaiment with the CFAS-I cohort fifteen years previously. Will examine influence of cognitive reserve on development of cognitive impairment.
4a. Study criteria: age range of participants at recruitment

Age in years from: 65
To (‘until death’ if applicable): until death

4b. Study criteria: inclusion criteria
All people in defined geographical areas aged over 65, registered with a general practitioner, including those in institutions.
4c. Study criteria: exclusion criteria
Terminal illness. Inability to speak English or Welsh.
5. Size of the cohort (i.e. number of participants enrolled)
1,000 – 5,000 participants
6a. Measures used to characterise participants
AGECAT
CamCog
6b. Additional measures for participants with a clinical disorder
No
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
No
7. Study design

  • Prospective cohort
  • Longitudinal

8. Cases matched by

  • Age
  • Sex

9a. Does the study include a specialised subset of control participants
No
9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date
01-08-2011
10a. ii) Data collection end date
31-03-2015
10a iii) Data collection for this study is

  • At the planning stage

10b. Plans to continue the cohort study beyond the current projected end date

11. Data collected
Only through the study
12. System in place to enable re-contact with patients for future studies
Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database

Yes/No % available
Data summarised in database  No
Database is web-based  No
Database on spreadsheet  No
Database is on paper  No
Other (specify)  No

Language used:

13b. Format and availability of data held as individual records

Yes/No % available
Data held as individual records  No
Data is web-based No
Data held on computer based records  No
Data held on cards  No
Other (specify)

Language used:

14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups

  • Access Committee mechanism

15. Data sharing policy specified as a condition of use
Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups
No
16b. i) Description of available tissues/samples/DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

17. Is information on biological characteristics available to other groups

  • No

Cohort – Maintaining function and well-being in later life

Population Cohorts
United Kingdom
Alzheimer’s disease & other dementias

 

 

Post
Filter